Sirio Pharma (300791): Results of Global expansion are emerging, overseas factories are expected to mitigate tariff impacts.

Event description: Sirio Pharma released the 2024 annual report, with total operating revenue of 4.211 billion yuan in 2024 (up 17.56% year-on-year); net income attributable to the parent company of 0.325 billion yuan (up 15.66% year-on-year), excluding non-recurring net income.

Changjiang SecuritiesApr 24 18:56

Sirio Pharma (300791): Actively adjusting, steadily advancing.

Investment highlights: In Q1 2025, the company achieved revenue of 0.954 billion yuan, an increase of 0.28% year-on-year; it achieved a net income attributable to shareholders of 0.069 billion yuan, a year-on-year increase of 8.90%; the net income attributable to shareholders after deducting non-recurring gains and losses was 0.065 billion yuan, a year-on-year increase of +.

SoochowApr 24 14:47

Sirio Pharma (300791): Breakthrough progress in emerging customer groups, and the scale effect of BF is gradually becoming apparent.

In 2024, the company's revenue / Net income / Net income after deduction of non-recurring items were 4.211 / 0.325 / 0.328 billion yuan (year-on-year +17.56% / +15.66% / +16.70%). Among them, the internal Business.

TianfengApr 24 07:17

Sirio Pharma (300791): Positive growth has returned in the China region, and diverse growth potential is emerging.

In Q1 2025, the company achieved revenue of 0.95 billion yuan (up 0.3% year on year); net income attributable to the parent company was 0.07 billion yuan (up 8.9% year on year); net income attributable to the parent company excluding non-recurring gains and losses was 0.07 billion yuan (up 0.2% year on year). Income performance base

ZheshangApr 24 00:00

Sirio Pharma (300791): Revenue growth rate narrows sequentially, and cost reduction and efficiency enhancement continue to advance.

On April 23, 2025, Sirio Pharma released the Q1 2025 report. The total revenue for Q1 2025 was 0.954 billion yuan (a year-on-year increase of 0.3%), with growth marginally slowing under high base conditions, and the net income attributed to the parent company was 0.69.

Huaxin SecuritiesApr 24 00:00

Sirio Pharma: 2025 First Quarter Report

SZSIApr 24 00:00 · Announcements